tirzepatide 5.0 Zepbound 5 mg/0.5 mL injection (single-dose pen) Images Which Weight-Loss Drug Works the

Below is an overview of how the two compare: Mechanism of Action: Retatrutide: Triple agonist (GLP-1, GIP, glucagon) Zepbound: Dual agonist (GLP-1, GIP) Developer: Retatrutide: Eli Lilly and Company (investigational) Zepbound: Eli Lilly and Company (approved) Regulatory Status: Retatrutide: Phase III clinical development Zepbound: FDA-approved for obesity, obstructive sleep apnea Weight Loss Efficacy: Retatrutide: Up to ~28.7% (68 weeks

While theres early promise GLP-1 receptor agonists may help sleep apnea, theres indication it may not be a short-term treatment

The samples were used for hematological and histopathological analyses

For instance, those without regular care or in areas with low specialist density might struggle to obtain a prescription